FORWARDNCT06010199
Clinical Phenotypes, Long-Term Outcomes, and Biobanking in Myocarditis
At risk: Primary completion moved 16 years 5 months later, primary endpoint(s) modified.
See at-risk trials from First Affiliated Hospital Xi'an Jiaotong University
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 5 versions: 5 with changes below. See every version on ClinicalTrials.gov ↗
Notable Primary completion pushed from Jul 31, 2030 to Dec 31, 2046 Show 9 more changesShow less
- Primary endpoint(s) modified
- Enrollment increased: 1000 → 5000 participants
- Eligibility criteria expanded, about 468 words
- Study completion pushed from Aug 31, 2030 to Dec 31, 2050
- Trial arms changed: 1 → 2
- Secondary endpoints: 4 to 13
- Study description expanded, about 1,106 words
- Site details revised
- Study title shortened, about 1 word
- Notable Trial status: Not Yet Recruiting to Recruiting
- Start date changed from estimate of Dec 31, 2024 to Aug 25, 2023
- Site details revised
- Notable Start date: Dec 31, 2023 to Dec 31, 2024v3
- Notable Start date: Aug 31, 2023 to Dec 31, 2023
- Primary endpoint revised
- Primary completion date: Aug 31, 2030 to Jul 31, 2030
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Secondary (13)
Show 8 moreShow less
Arms and interventions
Patients of all ages with physician-diagnosed myocarditis identified retrospectively from clinical records covering January 1, 2003, through the protocol amendment date. Available diagnostic, treatment, and outcome data will be collected from existing records. Historical outcomes will be reconstructed for up to five years after the qualifying clinical baseline. Patients may continue the remaining observation period or, after completing the historical period and the applicable consent process, begin a separate five-year prospective observation phase. They retain their original cohort assignment and unique identifier. Historical and newly initiated observation periods are recorded and analyzed separately. Previously stored samples may be used within applicable authorization and ethics approval. Sample availability is not required for inclusion. No treatment is assigned by the study.
Patients of all ages with physician-diagnosed myocarditis enrolled prospectively in the existing FORWARD study or newly recruited through December 31, 2045, excluding those assigned to the retrospective cohort. Previously enrolled patients retain their original identifiers and observation timelines. Clinical data and outcomes are collected at baseline, during hospitalization when applicable, at 1, 3, 6, and 12 months, and annually during years 2 through 5, using routine visits, medical records, or telephone contact. Treatment remains determined by treating clinicians. Optional additional blood or other body fluids may be collected during clinically required sampling, with applicable consent and safety assessment; tissue is limited to material remaining after clinical and pathological needs are met. No research-only puncture is performed. Lack of samples does not affect enrollment or follow-up.
Sites
1 site in 1 country
- First Affiliated Hospital of Xi'an Jiaotong UniversityXi'an, Shaanxi, China